LONITEN

This brand name is authorized in Austria, Australia, Brazil, Canada, Spain, Ireland, New Zealand, United Kingdom, South Africa

Active ingredients

The drug LONITEN contains one active pharmaceutical ingredient (API):

1 Minoxidil UNII 5965120SH1 - MINOXIDIL

Topical administration of minoxidil stimulates hair growth in men and women with androgenic alopecia. The mechanism of stimulating hair growth from minoxidil is not fully understood, but some actions of minoxidil include increasing hair diameter, stimulating new growth and prolonging the developmental phase, and stimulating hair follicle transition from resting phase (telogen) in the growth phase (regenerative). Read about Minoxidil

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C02DC01	Minoxidil	C Cardiovascular system → C02 Antihypertensives → C02D Arteriolar smooth muscle, agents acting on → C02DC Pyrimidine derivatives
Discover more medicines within C02DC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2313R
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 522717110061017
Country: CA	Health Products and Food Branch	Identifier(s): 00514497, 00514500
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 55636
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 143303, 143304, 196958, 36665, 36668, 36671
Country: IE	Health Products Regulatory Authority	Identifier(s): 77213
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 14832
Country: ZA	Health Products Regulatory Authority	Identifier(s): N/7.1/165, N/7.1/166